Lawrence Garbo is an Oncology physician affiliated with New York Oncology Hematology. OpenAlex indexes 63 publications with 2,862 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Patroon Creek Blvd
Suite 1
Albany, NY 122065004
Telephone
518-489-0044Registry record last updated 19 Mar 2019.
Clinical trials
- Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
Sponsor: US Oncology Research
- A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Sponsor: Mersana Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20212 payments
- Incyte CorporationProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.7%Microtubule Inhibitor25.1%Paclitaxel protein-bound particles72%Paclitaxel29%Part B, office-administered≥13 patientsCD38-directed Cytolytic Antibody17%Daratumumab100%Part B, office-administered≥19 patients+ 9 more classes in this area
Metabolism & gastrointestinal
19.8%Other antiemetics15.9%Fosaprepitant100%Part B, office-administered≥34 patientsSerotonin-3 Receptor Antagonist3.6%Granisetron hydrochloride51%Palonosetron hcl46%Ondansetron Hcl3%Ondansetron Odt1%Part D + Part B≥52 patients+ 5 more classes in this area
Blood & clotting
13.6%Erythropoiesis-stimulating Agent13.3%Darbepoetin alfa100%Part B, office-administered≥23 patientsFactor Xa inhibitor0.2%Eliquis92%Fondaparinux Sodium8%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Nischala Ammannagari, MD
New York Oncology Hematology
Isabel Cunningham, MD
New York Oncology Hematology
Harry Staszewski, MD
New York Oncology Hematology
Inder Lal, MD
New York Oncology Hematology
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”